DE69529708T2 - Herstellung von stabilen Zink-Insulinanalogen-Kristallen - Google Patents

Herstellung von stabilen Zink-Insulinanalogen-Kristallen

Info

Publication number
DE69529708T2
DE69529708T2 DE69529708T DE69529708T DE69529708T2 DE 69529708 T2 DE69529708 T2 DE 69529708T2 DE 69529708 T DE69529708 T DE 69529708T DE 69529708 T DE69529708 T DE 69529708T DE 69529708 T2 DE69529708 T2 DE 69529708T2
Authority
DE
Germany
Prior art keywords
preparation
insulin analog
zinc insulin
stable zinc
analog crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69529708T
Other languages
English (en)
Other versions
DE69529708D1 (de
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69529708(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69529708D1 publication Critical patent/DE69529708D1/de
Application granted granted Critical
Publication of DE69529708T2 publication Critical patent/DE69529708T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69529708T 1994-06-16 1995-06-14 Herstellung von stabilen Zink-Insulinanalogen-Kristallen Expired - Lifetime DE69529708T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (2)

Publication Number Publication Date
DE69529708D1 DE69529708D1 (de) 2003-04-03
DE69529708T2 true DE69529708T2 (de) 2003-10-16

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529708T Expired - Lifetime DE69529708T2 (de) 1994-06-16 1995-06-14 Herstellung von stabilen Zink-Insulinanalogen-Kristallen

Country Status (29)

Country Link
US (1) US5504188A (de)
EP (1) EP0692489B1 (de)
JP (1) JP3595607B2 (de)
KR (1) KR100369951B1 (de)
CN (1) CN1184234C (de)
AT (1) ATE233278T1 (de)
AU (1) AU697794B2 (de)
BR (1) BR9502798A (de)
CA (1) CA2151563C (de)
CO (1) CO4410205A1 (de)
CZ (1) CZ286066B6 (de)
DE (1) DE69529708T2 (de)
DK (1) DK0692489T3 (de)
ES (1) ES2188637T3 (de)
FI (1) FI952930A (de)
HU (1) HUT73495A (de)
IL (1) IL114152A (de)
IN (1) IN178919B (de)
MY (1) MY130551A (de)
NO (1) NO952334L (de)
NZ (1) NZ272358A (de)
PE (1) PE21896A1 (de)
PL (1) PL180968B1 (de)
RO (1) RO113529B1 (de)
RU (1) RU2156257C2 (de)
SI (1) SI0692489T1 (de)
TW (1) TW379228B (de)
YU (1) YU39595A (de)
ZA (1) ZA954942B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
CN1278737A (zh) * 1997-11-12 2001-01-03 阿尔萨公司 减少多肽自结合的方法
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
CA2346884A1 (en) * 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
WO2000023098A1 (en) * 1998-10-16 2000-04-27 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
AU2002255508B2 (en) * 2001-02-09 2008-04-03 Genentech, Inc. Crystallization of IGF-1
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP2243776A1 (de) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituierte Piperidine und ihre Verwendung zur Behandlung von Histamine H3 Rezeptor bedingten Erkrankungen
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP1615698B1 (de) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC Neue amide derivate und deren pharmazeutische verwendungen
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
JP5198280B2 (ja) 2005-11-17 2013-05-15 イーライ リリー アンド カンパニー グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
EP2241327A1 (de) 2006-03-15 2010-10-20 Novo Nordisk A/S Mischung von Amylin und Insulin
JP2009531376A (ja) 2006-03-28 2009-09-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ヒスタミンｈ３受容体活性を有するベンゾチアゾール
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EA016415B1 (ru) 2006-04-24 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
NZ571972A (en) 2006-05-29 2011-09-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2164458A1 (de) 2007-06-01 2010-03-24 Novo Nordisk A/S Stabile nichtwässrige pharmazeutische zusammensetzungen
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
ES2744384T3 (es) * 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
MX2010003979A (es) * 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
SG173112A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
EP2408808A4 (de) 2009-03-20 2015-05-06 Smartcells Inc Terminal-funktionalisierte konjugate und ihre verwendung
RU2508294C2 (ru) * 2009-08-11 2014-02-27 Биокон Лимитед Хроматографические способы и соединения, очищенные этими способами
EP2670773A1 (de) 2011-02-01 2013-12-11 Novo Nordisk A/S Reinigung von insulin
EP2670368A4 (de) 2011-02-03 2015-04-15 Pharmedica Ltd Neue im mund zersetzbare filme zur insulinverabreichung zwecks behandlung von diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (de) * 2014-08-26 2016-03-02 Carlina Technologies Verfahren aus Nanoausfällung von niedrige molekulargewichte Proteinen und Peptiden
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
WO2022109078A1 (en) 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE533252A (de) *
BE533298A (de) *
BE515508A (de) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29

Also Published As

Publication number Publication date
CA2151563C (en) 2007-08-07
HUT73495A (en) 1996-08-28
CA2151563A1 (en) 1995-12-17
YU39595A (sh) 1997-08-22
DE69529708D1 (de) 2003-04-03
NO952334D0 (no) 1995-06-13
RU2156257C2 (ru) 2000-09-20
AU2168195A (en) 1996-01-04
IL114152A (en) 1999-12-31
KR100369951B1 (ko) 2003-03-28
CZ286066B6 (cs) 2000-01-12
AU697794B2 (en) 1998-10-15
FI952930A (fi) 1995-12-17
NZ272358A (en) 1996-12-20
PL309099A1 (en) 1995-12-27
RO113529B1 (ro) 1998-08-28
BR9502798A (pt) 1996-06-04
ATE233278T1 (de) 2003-03-15
PL180968B1 (pl) 2001-05-31
MY130551A (en) 2007-06-29
CN1184234C (zh) 2005-01-12
ZA954942B (en) 1996-12-17
SI0692489T1 (en) 2003-06-30
PE21896A1 (es) 1996-06-15
EP0692489B1 (de) 2003-02-26
CO4410205A1 (es) 1997-01-09
JPH08169899A (ja) 1996-07-02
DK0692489T3 (da) 2003-03-31
NO952334L (no) 1995-12-18
IL114152A0 (en) 1995-10-31
IN178919B (de) 1997-07-19
ES2188637T3 (es) 2003-07-01
RU95110107A (ru) 1997-05-10
US5504188A (en) 1996-04-02
CN1128271A (zh) 1996-08-07
HU9501715D0 (en) 1995-08-28
JP3595607B2 (ja) 2004-12-02
TW379228B (en) 2000-01-11
FI952930A0 (fi) 1995-06-14
KR960000922A (ko) 1996-01-25
EP0692489A1 (de) 1996-01-17
CZ154195A3 (en) 1996-02-14

Similar Documents

Publication Publication Date Title
DE69529708D1 (de) Herstellung von stabilen Zink-Insulinanalogen-Kristallen
DE69013024T4 (de) Flüssigkristallpigment, Methode zur Herstellung und Verwendung in Bekleidungen.
DE3877529T2 (de) Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
ATE146956T1 (de) Blutfilter, gegebenenfalls resorbierbares
DE68923819T2 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE87828T1 (de) Verwendung des transformationswachstumsfaktors zur foerderung der wundheilung und zusammensetzung dafuer.
ATE164184T1 (de) Expression von menschlichen serum-albuminen in pichia pastoris
DE3580283D1 (de) Biologisch wirksame substanz mit hormonellen eigenschaften, verfahren zu ihrer herstellung und verwendung von histonen fuer medizinische zwecke.
ATE101620T1 (de) Mini-proinsulin, seine herstellung und verwendung.
ATE206051T1 (de) Verwendung einer zubereitung enthaltend amoxycillin und clavulansäure zur herstellung eines medikaments zur behandlung von bakteriellen infektionen bei pädiatrischen patienten
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
EP0709395A3 (de) Die Herstellung von stabilen Kristallen von Insulinanalogen
DE69318909T2 (de) Verfahren zur Herstellung von menschlichem Wachstumshormon
SE9402331D0 (sv) New use
GB8719741D0 (en) Regulating insulin treatment of diabetics
TH20759A (th) การเตรียมผลึกคล้ายอินซูลินกับสังกะสีที่เสถียร

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KOENIG SZYNKA TILMANN VON RENESSE, 40549 DUESSELDO